Terns Pharmaceuticals Inc

Terns Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company that develops small-molecule product candidates for oncology and obesity. Its pipeline includes TERN-701, an allosteric BCR-ABL tyrosine kinase inhibitor in Phase 1/2 trials for chronic myeloid leukemia (CML); TERN-501, a thyroid hormone receptor beta agonist in Phase IIa trials for metabolic dysfunction-associated steatohepatitis (MASH); and the TERN-801 series of GIPR modulators for obesity. Incorporated in 2016 and headquartered in Foster City, California, the company operates as a subsidiary of Merck Sharp & Dohme LLC as of May 4, 2026.